Table 1

Inhibitory activity of PJ-S21 on infection by primary HIV-1 strains

Primary strain

Subtype, Coreceptor use

ED₅₀* mg/ml

ED₉₀* mg/ml

92RW008

A, R5

0.50 ± 0.05

2.76 ± 0.28

94UG103

A, X4R5

1.42 ± 0.54

3.42 ± 0.98

92US657

B, R5

0.62 ± 0.11

2.86 ± 0.33

93IN101

C, R5

3.56 ± 1.10

8.87 ± 2.55

93MW959

C, R5

1.02 ± 0.19

3.54 ± 0.90

92UG001

D, X4R5

0.62 ± 0.17

2.94 ± 0.85

93THA051

E, X4R5

0.86 ± 0.01

4.09 ± 0.08

93BR020

F, X4R5

4.25 ± 0.78

8.31 ± 1.04

RU570

G, R5

0.42 ± 0.09

1.54 ± 0.16

BCF02

Group O, R5

0.59 ± 0.29

3.92 ± 0.27

* ED₅₀₍₉₀₎ = effective dose(s) of PJ-S21 for 50% (90%) inhibition of infection. One gram of PJ-S21 contains approximately 3.2 mg of the inhibitors adsorbed to starch from pomegranate juice.

Neurath et al. BMC Infectious Diseases 2004 4:41   doi:10.1186/1471-2334-4-41